Body Scan 2 combines a traditional platform scale with a retractable handheld sensor, enabling it to capture more than 60 health metrics in roughly a minute and a half. Several of these measurements are new to this version, and Withings says a few represent industry firsts for an in-home device.
One key capability is a hypertension risk alert. Instead of using a blood pressure cuff, the scale relies on a dedicated AI model to assess the risk of arterial hypertension, a major contributor to stroke. Another added feature focuses on signs of possible glycemic imbalance, offering early insight into issues such as prediabetes. The scale also debuts Impedance Cardiography (ICG) in a home product from Withings, providing information about how efficiently the heart circulates blood and potential factors influencing that function.
Withings notes that many of these biomarker assessments have undergone clinical validation, with the goal of empowering users to better understand their health and make informed lifestyle adjustments.
The company frames Body Scan 2 as a tool for addressing the “silent” effects of modern living - limited movement, chronic stress, poor sleep, and suboptimal diet - which can gradually lead to long-term conditions such as diabetes, hypertension, atrial fibrillation, and heart failure if not recognized early.
To support long-term insights, Body Scan 2 also generates a “Health Trajectory” score, illustrating how habit changes may affect future health outcomes.
Like previous Withings smart scales, Body Scan 2 connects with popular health platforms, including apps linked via Android Health Connect such as Fitbit. The device can sync through Wi-Fi or Bluetooth and is rated for up to 15 months of battery life.
Withings plans to launch Body Scan 2 in Q2 2026, with U.S. pricing set at $599, which is about $100 higher than the previous model.
Newer Articles
- Motorola Showcases Razr Fold and New AI Concepts at CES
- Inside the AI Startup Boom Powering the $1.5 Trillion Market
- Common Food Preservatives Tied to Increased Cancer and Diabetes Risk
